Navigation Links
New Venture Funding for Alzheimer's Disease Drug Developer
Date:1/12/2009

MADISON, Wis., Jan. 12 /PRNewswire/ -- Mithridion, Inc., a drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease (AD), announced today that it held an initial closing of $2.9 million in Series B Preferred Stock financing. The company will use the funds for the clinical development of MCD-386, its lead drug candidate, aimed at stopping or slowing down disease progression and improving memory and cognition in this devastating disorder. The company has raised $7.4 million to date in equity funding.

Venture Investors (VI - Madison, Wis.) led this latest round of financing. The State of Wisconsin Investment Board and Wisconsin Investment Partners, both of Madison, Wis., and Rocket Venture Fund (Toledo. Ohio), all existing shareholders, also participated in the latest funding. Mithridion plans to hold a final closing with respect to this financing on or before March 31, 2009.

John Neis, Managing Director of VI, will join Mithridion's board of directors.

"This new funding will enable Mithridion not only to advance MCD-386 in Phase I trial, but will also support the development of exciting drug leads for AD and schizophrenia in our preclinical pipeline," said Trevor M. Twose, Ph.D., the company's Chief Executive. "We greatly appreciate the continued support of our shareholders," he added.

Five million Americans suffer from Alzheimer's disease today, and the number will grow as baby-boomers age. The market for Alzheimer's disease drugs exceeds $4 billion, but is currently underserved, and may grow to greater than $10 billion with the development of drugs that are more effective.

MCD-386 is highly selective for the M1-type muscarinic receptor. In preclinical laboratory tests, MCD-386 appears to replace deficient brain acetylcholine activity, similar to that caused by AD. This drug is intended to improve memory and cognition, with improved tolerability compared to previously tested M1-selective muscarinic drugs. MCD-386 also appeared to activate alpha-secretase enzymes, which might reduce or prevent the loss of brain cells in AD by preventing the formation of amyloid beta. In preclinical laboratory tests, MCD-386 appeared to be superior to the best first-generation drug candidates of this type.

Four of the five currently approved drugs slow down the breakdown of acetylcholine, thereby boosting its concentration to overcome the deficiency in AD. However, unlike these drugs, MCD-386 is designed to mimic only the M1 activity of acetylcholine, with potentially greater efficacy and less side-effects.

Mithridion's headquarters and preclinical drug research laboratories are in Madison, Wis., and its semi-virtual clinical drug development team operates out of Toledo, Ohio. The Company commenced operations in February 2006. During 2008, Mithridion acquired Cognitive Pharmaceuticals Ltd., (Toledo, Ohio), raised $2.3 million of Series B funding, and successfully completed the first stage of Phase I clinical trials of MCD-386.

Venture Investors is a venture capital firm with $190 million under management. The firm invests in seed and early-stage life science and technology companies in the Midwest, with a primary focus on opportunities that spin out of the region's leading research universities. Formed in 1982, Venture Investors has offices strategically located next to the country's third and fourth largest research institutions in Ann Arbor, Mich., and Madison, Wisc. For additional information on the firm, visit www.ventureinvestors.com.


'/>"/>
SOURCE Mithridion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
2. NTU and Insightra Medical Inc. release their first joint venture medical device
3. Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals
4. STAAR Surgical to Purchase Canons Interest in Japanese Joint Venture
5. Harmony Information Systems Raises $28 Million in Series B Financing from JMI Equity, Updata Partners, ORIX Venture Finance and Comerica Bank
6. Venture Health Group Selects Planet DDS Web-based Practice Management Software
7. HLM Venture Partners Leads Series B Financing of CaseNET, Inc.
8. RadPharm Announces $10 million Series B Financing, led by Siemens Venture Capital
9. MM2 Group Establishes New Venture for Sofgel Manufacture in China
10. Radius Ventures Announces Promotion of Dr. David Stoffel to Partner
11. STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... ... of non-invasive devices and systems for monitoring cardiopulmonary diseases, announced today that it ... used to complete regulatory submissions and fund final engineering and initial production of ...
(Date:7/20/2017)... ROUGE, La. (PRWEB) , ... July 20, 2017 , ... ... to the staff. Dr. Dunbar received his BS in Biology from LSU, graduating summa ... the Medical School Class President. After his residency in St. Louis, Dr. Dunbar moved ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... the Business Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 is now available ... to this effort through Guild collaborative teams. , Non-members may download the ...
(Date:7/20/2017)... Charlotte, NC (PRWEB) , ... July 20, 2017 , ... ... announces the latest innovation to their product line: the AVE 2 birthing bed. , ... 2 helps bring a new level of comfort and efficiency to every phase of ...
(Date:7/20/2017)... ... ... At Creekwood Dental Arts, Drs. Donna G. Miller and Michelle Hinds are ... in Waco, TX, using the latest dental technology for digital imagery and bite ... details in the oral cavity for accurate diagnoses and customized care plans. These tools ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... 5, 2017 Wolfmet 3D  printed tungsten collimator manufactured by ... and manufacturing combine to progress molecular radiotherapy imaging. ... are unable to accurately quantify the radiation absorbed by those ... the success of this radiotherapy treatment has been available — ... ...
(Date:6/30/2017)... 30, 2017 In vitro diagnostics market firm ... May, at least ten diagnostic companies have successfully completed ... offerings and a loan facility.  The size of these ... million.  Kalorama Information provides a monthly IVD Market ... Knowledge Center. ...
(Date:6/20/2017)... LAGUNA HILLS, Calif. , June 20, ... data that validate the use of MMprofiler with SKY92, ... multiple myeloma (MM). In a poster presentation at the ... (EHA) in Madrid, Spain , SkylineDx ... identifying high-risk elderly patients. In a ...
Breaking Medicine Technology: